Formed in 1998, Skinvisible operates in the consumer sector of the household and personal products industry. The company focuses on designing "polymer delivery vehicles" (PDVs), trademarked as Invisicare®, to established makers of dermatology, medical, cosmetic, and skincare products.
Invisicare® helps a product's active ingredients stay on your skin or penetrate your skin, depending on the product. Invisicare's possible uses and applications are numerous. You can find it in products such as acne prevention creams, antimicrobial hand sanitizer lotions, sun care products, skincare moisturizers, sunless tanning products, as well as various dermatology, women's health, pain management, and other pharmaceutical products for various disorders. Going forward, SKVI wants to develop polymer formulations that can successfully be incorporated into other products. SKVI has many promising products under development and ready to market, pending governmental approval where needed.
Consumer healthcare product companies require knowledgeable management with the business experience and scientific knowledge to put all the pieces of a profitable company together. In this case, SKVI has the necessary talent.
Leading the company is Mr. Terry H. Howlett. Mr. Howlett founded Skinvisible, Inc. in 1998 and has served as its CEO, CFO, and a Director since its inception. Mr. Howlett's diversified background includes senior management, marketing, and sales positions with both established and emerging businesses, including two prior positions at healthcare companies. Howlett is a primary driver of SKVI's direction and vision.
The other Director of the SKVI is Mr. Greg McCartney, who joined the Board in 2005. Currently, Mr. McCartney is Managing Director of Taylor, Butterfield & Worth Asset Management Corporation. Previously, Mr. McCartney was the Chairman of the Board for Genesis Bioventures (formerly BioLabs) and also formerly served as their CEO. Mr. McCartney has over 20 years experience serving as officer and director of both private and public companies in various manufacturing and technology industries.
Fronting the technical end of the company is Dr. James Roszell, a chemist with over 35 years experience in product formulation, experimental design, analysis, and method validation. Since joining Skinvisible in 1998, his primary focus has been in research and development of the company's technology, including alternative uses and delivery methods. Dr. Roszell played a key role in the development of Skinvisible's Patent Number 6.756.059 and SKVI's four pending patents. His background prior to SKVI includes work experience in the chemical, pharmaceutical, environmental, and clinical laboratory sectors. His scientific knowledge is a prime asset to the company.
Another key part of the management team is Ms. Doreen McMorran, head of Business Development. Ms. McMorran's career includes 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales, and marketing. McMorran has sold skin care products to some of the top names in business, such as Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis, and Graceway. Her past employment includes six years with Astra Pharma and senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing, and operations.
To learn more about the company and its Invisicare® technology, visit skinvisible.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net